Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency

Neurobiology of Aging

Volumn 34, Issue 12, 2013, Pages 2843-2852

  Wu, Jiang ^a,b   Bie, Bihua ^a   Yang, Hui ^a   Xu, Jijun J ^a   Brown, David L ^a   Naguib, Mohamed ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid; CX3CR1; Hippocampus; Histone acetylation; Microglia

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CHEMOKINE RECEPTOR CX3CR1; GLUTAMIC ACID; HISTONE H3; INTERLEUKIN 1BETA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; CX3CR1 GENE; GENE; GENE EXPRESSION REGULATION; GENE REPRESSION; HIPPOCAMPAL CA1 REGION; HISTONE ACETYLATION; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MICROGLIA; NERVE CELL LESION; NERVE STIMULATION; NEUROTRANSMISSION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SPATIAL MEMORY;

ALZHEIMER'S DISEASE; AMYLOID; CX3CR1; HIPPOCAMPUS; HISTONE ACETYLATION; MICROGLIA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CA1 REGION, HIPPOCAMPAL; DEPRESSION, CHEMICAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MALE; MEMORY DISORDERS; MICROINJECTIONS; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHEMOKINE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SYNAPSES; UP-REGULATION;

EID: 84884150739     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.06.003     Document Type: Article

References (49)

1. Ahmed T., Enam S.A., Gilani A.H. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 2010, 169:1296-1306.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
3. Barry A.E., Klyubin I., Mc Donald J.M., Mably A.J., Farrell M.A., Scott M., Walsh D.M., Rowan M.J. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP invivo is prevented by immunotargeting cellular prion protein. J.Neurosci. 2011, 31:7259-7263.
4. Bie B., Brown D.L., Naguib M. Increased synaptic GluR1 subunits in the anterior cingulate cortex of rats with peripheral inflammation. Eur. J. Pharmacol. 2011, 653:26-31.
5. Bie B., Brown D.L., Naguib M. Synaptic plasticity and pain aversion. Eur. J. Pharmacol. 2011, 667:26-31.
6. Bie B., Wang Y., Cai Y.Q., Zhang Z., Hou Y.Y., Pan Z.Z. Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward. Neuropsychopharmacology 2012, 37:2780-2788.
7. Bie B., Zhang Z., Cai Y.Q., Zhu W., Zhang Y., Dai J., Lowenstein C.J., Weinman E.J., Pan Z.Z. Nerve growth factor-regulated emergence of functional delta-opioid receptors. J.Neurosci. 2010, 30:5617-5628.
8. Bie B., Zhu W., Pan Z.Z. Ethanol-induced delta-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala. Neuroscience 2009, 160:348-358.
9. Bie B., Zhu W., Pan Z.Z. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. J.Pharmacol. Exp. Ther. 2009, 329:290-296.
10. Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., Huang D., Kidd G., Dombrowski S., Dutta R., Lee J.C., Cook D.N., Jung S., Lira S.A., Littman D.R., Ransohoff R.M. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006, 9:917-924.
11. Chacon M.A., Barria M.I., Soto C., Inestrosa N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 2004, 9:953-961.
12. Cho S.H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J.Biol. Chem. 2011, 286:32713-32722.
13. Denes A., Ferenczi S., Halasz J., Kornyei Z., Kovacs K.J. Role of CX3CR1(fractalkine receptor) in brain damage and inflammation inducedbyfocal cerebral ischemia in mouse. J.Cereb. Blood Flow Metab. 2008, 28:1707-1721.
14. Donnelly D.J., Longbrake E.E., Shawler T.M., Kigerl K.A., Lai W., Tovar C.A., Ransohoff R.M., Popovich P.G. Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J.Neurosci. 2011, 31:9910-9922.
15. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J.Neural Transm. 2006, 113:1685-1695.
16. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H., Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
17. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010, 6:232-241.
18. Gräff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
19. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7611-7615.
20. Gu Z., Steinmetz L.M., Gu X., Scharfe C., Davis R.W., Li W.H. Role of duplicate genes in genetic robustness against null mutations. Nature 2003, 421:63-66.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., Botti P., Bacon K.B., Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:10896-10901.
23. Hickman S.E., Allison E.K., El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J.Neurosci. 2008, 28:8354-8360.
24. Koenigsknecht-Talboo J., Meyer-Luehmann M., Parsadanian M., Garcia-Alloza M., Finn M.B., Hyman B.T., Bacskai B.J., Holtzman D.M. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J.Neurosci. 2008, 28:14156-14164.
25. Lee S., Varvel N.H., Konerth M.E., Xu G., Cardona A.E., Ransohoff R.M., Lamb B.T. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 2010, 177:2549-2562.
26. Liang H., Li W.H. Functional compensation by duplicated genes in mouse. Trends Genet. 2009, 25:441-442.
27. Masliah E. Neuropathology: Alzheimer's in real time. Nature 2008, 451:638-639.
28. Maze I., Nestler E.J. The epigenetic landscape of addiction. Ann. N. Y. Acad. Sci. 2011, 1216:99-113.
29. Maze I., Noh K.M., Allis C.D. Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology 2012, 38:3-22.
30. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
31. Naguib M., Bie B., Ting A.H. Fundamental concepts of epigenetics for consideration in anesthesiology. Curr. Opin. Anaesthesiol. 2012, 25:434-443.
32. Old E.A., Malcangio M. Chemokine mediated neuron-glia communication andaberrant signalling in neuropathic pain states. Curr. Opin. Pharmacol. 2012, 12:67-73.
33. Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L., Ragozzino D., Gross C.T. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York. fourth ed.
35. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
36. Prinz M., Priller J. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J.Neuroimmunol. 2010, 224:80-84.
37. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J.Neurosci. 2005, 25:1904-1913.
38. Ransohoff R.M. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009, 31:711-721.
39. Ransohoff R.M., Cardona A.E. The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262.
40. Re D.B., Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. Nat. Neurosci. 2006, 9:859-861.
41. Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J.Neurosci. 2011, 31:1688-1692.
42. Sioud M. siRNA delivery invivo. Methods Mol. Biol. 2005, 309:237-249.
43. Solito E., Sastre M. Microglia function in Alzheimer's disease. Front. Pharmacol. 2012, 3:14.
44. Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog. Neurobiol. 2012, 99:226-245.
45. Stephan A., Laroche S., Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J.Neurosci. 2001, 21:5703-5714.
46. Streit W.J. Microglial senescence: does the brain's immune system have an expiration date?. Trends Neurosci. 2006, 29:506-510.
47. Wu J., Bie B., Yang H., Xu J.J., Brown D.L., Naguib M. Activation of the CB(2) receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 2013, 34:791-804.
48. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
49. Xia M.Q., Bacskai B.J., Knowles R.B., Qin S.X., Hyman B.T. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: invitro ERK1/2 activation and role in Alzheimer's disease. J.Neuroimmunol. 2000, 108:227-235.